Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Deping Wang.
Journal of Medicinal Chemistry | 2008
Joseph A. Ippolito; Zoltan F Kanyo; Deping Wang; François Franceschi; Peter B. Moore; Thomas A. Steitz; Erin M. Duffy
The oxazolidinone antibacterials target the 50S subunit of prokaryotic ribosomes. To gain insight into their mechanism of action, the crystal structure of the canonical oxazolidinone, linezolid, has been determined bound to the Haloarcula marismortui 50S subunit. Linezolid binds the 50S A-site, near the catalytic center, which suggests that inhibition involves competition with incoming A-site substrates. These results provide a structural basis for the discovery of improved oxazolidinones active against emerging drug-resistant clinical strains.
Bioorganic & Medicinal Chemistry Letters | 2008
Jiacheng Zhou; Ashoke Bhattacharjee; Shili Chen; Yi Chen; Erin M. Duffy; Jay J. Farmer; Joel Goldberg; Roger Hanselmann; Joseph A. Ippolito; Rongliang Lou; Alia Orbin; Ayomi Oyelere; Joe Salvino; Dane M. Springer; Jennifer Tran; Deping Wang; Yusheng Wu; Graham Johnson
We have developed a first generation of hybrid sparsomycin-linezolid compounds into a new family of orally bioavailable biaryloxazolidinones that have activity against both linezolid-susceptible and -resistant gram-positive bacteria as well as the fastidious gram-negative bacteria Haemophilus influenzae and Moraxella catarrahalis. The convergent synthesis of these new compounds is detailed.
Bioorganic & Medicinal Chemistry Letters | 2008
Jiacheng Zhou; Ashoke Bhattacharjee; Shili Chen; Yi Chen; Erin M. Duffy; Jay J. Farmer; Joel Goldberg; Roger Hanselmann; Joseph A. Ippolito; Rongliang Lou; Alia Orbin; Ayomi Oyelere; Joe Salvino; Dane M. Springer; Jennifer Tran; Deping Wang; Yusheng Wu; Graham Johnson
From the X-ray crystal structures of linezolid and the non-selective antibiotic sparsomycin, we have derived a new family of hybrid oxazolidinones. From this initial compound set we have developed a new biaryloxazolidinone scaffold that shows both potent antimicrobial activity as well as selective inhibition of ribosomal translation. The synthesis of these compounds is outlined.
Archive | 2003
Deping Wang; Joyce A. Sutcliffe; Adegboyega K. Oyelere; Timothy S. McConnell; Joseph A. Ippolito; John N. Abelson; Dane M. Springer; Joseph M. Salvino; Rongliang Lou; Joel Goldberg; Jay J. Farmer; Erin M. Duffy; Ashoke Bhattacharjee
Archive | 2004
Jiacheng Zhou; Ashoke Bhattacharjee; Shili Chen; Yi Chen; Jay J. Farmer; Joel Goldberg; Roger Hanselmann; Rongliang Lou; Alia Orbin; Adegboyega K. Oyelere; Josseph M. Salvino; Dane M. Springer; Jennifer Tran; Deping Wang; Yusheng Wu
Archive | 2004
Shili Chen; Jiacheng Zhou; Yusheng Wu; Deping Wang; Joseph M. Salvino; Adegboyega K. Oyelere; Rongliang Lou
Archive | 2004
Jiacheng Zhou; Ashoke Bhattacharjee; Shili Chen; Yi Chen; Jay J. Farmer; Joel Goldberg; Roger Hanselmann; Rongliang Lou; Alia Orbin; Adegboyega K. Oyelere; Joseph M. Salvino; Dane M. Springer; Jennifer Tran; Deping Wang; Yusheng Wu
Archive | 2004
Shili Chen; Jiacheng Zhou; Yunsheng Wu; Deping Wang; Joseph M. Salvino; Adegboyega K. Oyelere; Rongliang Lou; Ashoke Bhattacharjee; Yi Chen
Archive | 2004
Jiacheng Zhou; Ashoke Bhattacharjee; Shili Chen; Yi Chen; Jay J. Farmer; Joel Goldberg; Roger Hanselmann; Rongliang Lou; Alia Orbin; Adegboyega K. Oyelere; Joseph M. Salvino; Dane M. Springer; Jennifer Tran; Deping Wang; Yusheng Wu
Archive | 2004
Rongliang Lou; Ashoke Bhattacharjee; Yi Chen; Shili Chen; Oyelere K. Adegboyega; Deping Wang; Yusheng Wu; Jiacheng Zhou